Latest Contracts News

Johns Lyng Group delivered steady FY25 financial results with revenue growth and strong core operations, while securing a $1.1 billion acquisition offer from Pacific Equity Partners.

Centrepoint Alliance reported a 13.5% revenue increase and a 30.6% rise in pre-tax profit for the year ended June 2025, yet net profit after tax fell by 33.7%. The company maintained its final dividend at 1.75 cents per share.

Australian Clinical Labs reported a 6.4% revenue increase and an 8.7% rise in underlying EBIT for FY25, maintaining disciplined growth and operational efficiency in a complex healthcare environment.

Web Travel Group signals strong momentum heading into FY26, projecting record EBITDA and a robust $3.1 billion in first-half Total Transaction Value despite geopolitical headwinds.

WebBeds reported a 22% rise in Total Transaction Value to nearly $5 billion for FY25, while EBITDA fell 14% amid margin pressures and higher costs. The company is targeting $10 billion TTV by FY30 with improved profitability.

Fortescue Ltd reported a solid FY25 with record iron ore shipments and a strong profit, while making significant strides in its decarbonisation agenda including renewable energy projects and green metal production.

Noumi Limited reported a 13% rise in adjusted operating EBITDA for FY25, driven by strong growth in its plant-based milks and dairy segments. The company has resolved legacy litigation issues and is now focused on navigating the $610 million convertible note maturity due in 2027.

Acusensus Limited reported a robust FY25 with 20% revenue growth and a significant 84% jump in total contract value, setting the stage for an ambitious FY26 forecast of up to 41% revenue increase.

Acusensus Limited reported a 20% increase in revenue to $59.35 million for FY25, driven by new and expanded contracts across Australia, New Zealand, the US, and the UK. However, net losses widened by 72.3%, reflecting higher operating expenses and ongoing litigation costs.

Robex Resources confirms steady progress at its Kiniero Gold Project in Guinea, maintaining schedule and budget for first gold production in late 2025. Key construction milestones and drilling activities highlight the project’s momentum.

Firebrick Pharma has secured an exclusive licensing agreement with Innorini Pte Ltd to distribute Nasodine products across Singapore, Malaysia, Brunei, and Mauritius, aiming to reduce marketing expenses and broaden market access.

Imricor Medical Systems reported a sharp 52% revenue decline and a 92% increase in net loss for H1 2025, offset by a $42.8 million equity raise boosting liquidity. The company is investing heavily in European sales and clinical trials while pursuing FDA approval.